Literature DB >> 6486173

A private view of heterozygosity: eight-year follow-up study on carriers of the Tay-Sachs gene detected by high school screening in Montreal.

S Zeesman, C L Clow, L Cartier, C R Scriver.   

Abstract

We surveyed 264 persons (132 carriers, 132 matched noncarriers) screened for Tay-Sachs heterozygosity during 1974-76 in a program directed at senior high school students in Montreal. Among 198 who apparently received the questionnaire in 1982, the response rate was 42% (38 carriers, 45 noncarriers; age range 21-26 yr). Respondents and nonrespondents had no apparent demographic differences. Of eight unable to remember their genotype only one was a carrier (these persons were excluded from the study). The subjects were: single (75%), married (20%), engaged (3%), divorced (1%); 32% of carriers were engaged or married vs 16% of noncarriers. (There were no carrier couples in our sample, but one such couple, who married after being screened in the high school program, requested amniocentesis in 1981.) Only three of the 12 spouses or fiancé(s) of carriers have not been tested (vs 3 of 6 noncarrier partners). Only 19% of carriers now attach any "worry" to heterozygosity (vs 46% at the earlier time of test disclosure, P = 0.001); carriers with spouses or fiancé(e)s are less "worried" than unattached carriers. Only 3% of carriers claim they would change marriage plans if their fiancé(e) was also a carrier. Carriers and noncarriers uniformly approve (96%) genetic screening for themselves and for other mutant genotypes; 92% of carriers and 95% of noncarriers approve being screened in high school. These findings indicate that Canadians screened in high school: 1) have largely positive attitudes toward genetic screening long after the experience, and 2) are making appropriate use of the test result.

Entities:  

Mesh:

Year:  1984        PMID: 6486173     DOI: 10.1002/ajmg.1320180424

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  26 in total

1.  Carrier testing of children for two X linked diseases in a family based setting: a retrospective long term psychosocial evaluation.

Authors:  O Järvinen; A M Aalto; A E Lehesjoki; M Lindlöf; I Söderling; A Uutela; H Kääriäinen
Journal:  J Med Genet       Date:  1999-08       Impact factor: 6.318

2.  Attitudes of high school students toward carrier screening and prenatal diagnosis of cystic fibrosis.

Authors:  Sharon J Durfy; Andrea Page; Barry Eng; Patricia L Chang; John S Waye
Journal:  J Genet Couns       Date:  1994-06       Impact factor: 2.537

3.  A qualitative study exploring genetic counsellors' experiences of counselling children.

Authors:  Fiona Ulph; James Leong; Cris Glazebrook; Ellen Townsend
Journal:  Eur J Hum Genet       Date:  2010-06-09       Impact factor: 4.246

4.  Cystic fibrosis genotypes and views on screening are both heterogeneous and population related.

Authors:  C R Scriver; T M Fujiwara
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

5.  Laboratory policies and practices for the genetic testing of children: a survey of the Helix network.

Authors:  D C Wertz; P R Reilly
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Effects of genetic screening on perceptions of health: a pilot study.

Authors:  T M Marteau; M van Duijn; I Ellis
Journal:  J Med Genet       Date:  1992-01       Impact factor: 6.318

7.  Screening for lysosomal storage disorders--a clinical perspective.

Authors:  Janice M Fletcher
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

8.  What do young people think about screening for cystic fibrosis?

Authors:  E Cobb; S Holloway; R Elton; J A Raeburn
Journal:  J Med Genet       Date:  1991-05       Impact factor: 6.318

9.  Guidelines for genetic testing of healthy children.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

10.  Costs, effects, and savings of screening for cystic fibrosis gene carriers.

Authors:  M F Wildhagen; H B Hilderink; J G Verzijl; J B Verheij; L Kooij; T Tijmstra; L P ten Kate; J D Habbema
Journal:  J Epidemiol Community Health       Date:  1998-07       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.